Table 1.
Charateristics of the study population.
Figure 1.
Serum TRAIL levels in AMI patients and healthy individuals.
Levels of TRAIL were determined by ELISA in sera from AMI patients (analyzed at the indicated times post AMI) and from healthy control subjects. Horizontal bars are median, upper and lower edges of box are 75th and 25th percentiles, lines extending from box are 10th and 90th percentiles.
Figure 2.
Correlation between serum levels of TRAIL and negative prognostic markers.
Inverse correlation between serum levels of TRAIL and CK (A), between TRAIL and CK-MB (B) and between TRAIL and BNP (C) in AMI patients. Coefficients of correlation (R) are indicated.
Table 2.
Association between TRAIL and CK adjusted for demographic and clinical parameters (multivariable linear regression analysis).
Table 3.
Association between TRAIL and CK-MB adjusted for demographic and clinical parameters (multivariable linear regression analysis).
Table 4.
Association between TRAIL and BNP adjusted for demographic and clinical parameters (multivariable linear regression analysis).
Figure 3.
Serum TRAIL levels in AMI patient with respect to adverse clinical events.
Serum levels of TRAIL were analyzed in AMI patient who died or experienced HF (with events) either during the acute phase (in-hospital) or in the follow-up (12 months after AMI) with respect to the other AMI patients (without events). Horizontal bars are median, upper and lower edges of box are 75th and 25th percentiles, lines extending from box are 10th and 90th percentiles.
Table 5.
Cox proportional-hazards regression tests for predictors of death or new-onset HF after AIC selection.